BACKGROUND: We hypothesized that serum gamma-glutamyltransferase (GGT) would positively predict the risk of microalbuminuria, a frequent consequence of both diabetes and hypertension, because serum GGT predicted diabetes and hypertension in dose-response relationships. METHODS: In this prospective study, 2478 black and white men and women without microalbuminuria at year 10 provided urine samples 5 years later. Year 10 GGT cutpoints were 12, 18, and 29 U/L. RESULTS: The incidence of microalbuminuria across year 10 GGT categories was U-shaped. Adjusted odds ratios across quartiles of serum GGT were 1.0, 0.39, 0.54, and 0.94 (P <0.01 for quadratic term), but the shape of association depended on the status of hypertension or diabetes (P <0.01 for interaction). Among individuals who ever had hypertension or diabetes, year 10 serum GGT showed a clear positive dose-response association with incident microalbuminuria (P <0.01 for trend), whereas among individuals with neither hypertension nor diabetes during the study, year 10 GGT showed a U-shaped association with it (P = 0.01 for quadratic term). When the long-term risk was evaluated in 3895 participants based on serum GGT at year 0 and prevalence of microalbuminuria at year 10 or year 15, the trends were similar but weaker than those of short-term incidence risk. CONCLUSIONS: Serum GGT within the physiologic range predicted microalbuminuria among patients with hypertension or diabetes and may act as a predictor of microvascular and/or renal complications in these vulnerable groups. GGT showed a U-shaped association with microalbuminuria among persons who did not develop either hypertension or diabetes.
BACKGROUND: We hypothesized that serum gamma-glutamyltransferase (GGT) would positively predict the risk of microalbuminuria, a frequent consequence of both diabetes and hypertension, because serum GGT predicted diabetes and hypertension in dose-response relationships. METHODS: In this prospective study, 2478 black and white men and women without microalbuminuria at year 10 provided urine samples 5 years later. Year 10 GGT cutpoints were 12, 18, and 29 U/L. RESULTS: The incidence of microalbuminuria across year 10 GGT categories was U-shaped. Adjusted odds ratios across quartiles of serum GGT were 1.0, 0.39, 0.54, and 0.94 (P <0.01 for quadratic term), but the shape of association depended on the status of hypertension or diabetes (P <0.01 for interaction). Among individuals who ever had hypertension or diabetes, year 10 serum GGT showed a clear positive dose-response association with incident microalbuminuria (P <0.01 for trend), whereas among individuals with neither hypertension nor diabetes during the study, year 10 GGT showed a U-shaped association with it (P = 0.01 for quadratic term). When the long-term risk was evaluated in 3895 participants based on serum GGT at year 0 and prevalence of microalbuminuria at year 10 or year 15, the trends were similar but weaker than those of short-term incidence risk. CONCLUSIONS: Serum GGT within the physiologic range predicted microalbuminuria among patients with hypertension or diabetes and may act as a predictor of microvascular and/or renal complications in these vulnerable groups. GGT showed a U-shaped association with microalbuminuria among persons who did not develop either hypertension or diabetes.
Authors: Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Giuseppe Lippi; Giacomo Zoppini; Michel Chonchol Journal: Clin J Am Soc Nephrol Date: 2010-08-19 Impact factor: 8.237
Authors: G Targher; L Bertolini; M Chonchol; S Rodella; G Zoppini; G Lippi; L Zenari; E Bonora Journal: Diabetologia Date: 2010-04-06 Impact factor: 10.122
Authors: Robert M Wilechansky; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Emelia J Benjamin; Michelle T Long Journal: Liver Int Date: 2019-05-24 Impact factor: 5.828
Authors: Mahmut Ilker Yilmaz; Faruk Turgut; Mehmet Kanbay; Mutlu Saglam; Alper Sonmez; Halil Yaman; Seref Demirbas; Hilmi Umut Unal; Mahmut Gok; Murat Karaman; Seyit Ahmet Ay; Erkan Demirkaya; Adrian Covic; Juan Jesus Carrero Journal: Int Urol Nephrol Date: 2012-12-15 Impact factor: 2.370